Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its price target reduced by Royal Bank of Canada from $165.00 to $161.00 ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the ...

Biotech company Sarepta Therapeutics (NASDAQ:SRPT) announced better-than-expected revenue in Q4 CY2024, with sales up 65.9% ...

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “sell” rating reiterated by stock analysts at HC ...

Q4 2024 Earnings Call Transcript February 26, 2025 Sarepta Therapeutics, Inc. beats earnings expectations. Reported EPS is $1 ...

BofA lowered the firm’s price target on Sarepta (SRPT) to $210 from $217 and keeps a Buy rating on the shares. Management is confident in FY25 ...

RBC Capital analyst Brian Abrahams maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) yesterday and set a price target of ...

We recently compiled a list of the 15 Stocks That Will Go to The Moon According to Analysts. In this article, we are going to ...

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Sarepta Therapeutics Inc. (SRPT) on Wednesday reported fourth-quarter profit of $159 million. On a per-share basis, the Cambridge, Massachusetts-based ...

Established inaugural $600 million senior secured revolving credit facility: This instrument, available to Sarepta because of the Company’s financial strength and positive business outlook ...

We recently published a list of 15 Best Fast Growth Stocks To Buy Right Now. In this article, we are going to take a look at ...

(RTTNews) - Sarepta Therapeutics (SRPT) announced a profit for its fourth quarter that increased from the same period last year but missed the Street estimates. The company's bottom line totaled $ ...